Survival in patients with renal cell carcinoma and brain metastases: an update of the Renal Graded Prognostic Assessment.

In 1049 patients with renal cell carcinoma and brain metastases treated from 2016–2022, median overall survival was 20·0 months and varied widely by updated Renal GPA.

• Why it matters: Brain metastases in renal cell carcinoma are common and serious, and clinicians need updated prognostic tools reflecting contemporary multi-modal therapies and trial stratification.
• What they did: An international consortium of 21 academic institutions analyzed uniformly curated retrospective data, identified survival prognostic factors via combined multivariable analyses, and updated the Renal GPA; intracranial progression-free survival was time to first salvage treatment.
• The result: Survival improved versus legacy cohorts (9·6 months and 12·0 months), and intracranial progression-free survival correlated with overall survival (Spearman 0·74, p<0·0001), enabling survival estimation and trial design/eligibility refinement.

AI summary of the abstract · may contain errors · not medical advice · read the paper.